Psyence Biomedical (Psyence Biomedical) Debt-to-EBITDA : 0.00 (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Psyence Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.00 Mil. Psyence Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.00 Mil. Psyence Biomedical's annualized EBITDA for the quarter that ended in Mar. 2023 was $-3.13 Mil. Psyence Biomedical's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Psyence Biomedical's Debt-to-EBITDA or its related term are showing as below:

PBM's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

Psyence Biomedical Debt-to-EBITDA Historical Data

The historical data trend for Psyence Biomedical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Debt-to-EBITDA Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-EBITDA

N/A

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Debt-to-EBITDA	N/A	-	-

Competitive Comparison of Psyence Biomedical's Debt-to-EBITDA

For the Biotechnology subindustry, Psyence Biomedical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Debt-to-EBITDA falls into.

Psyence Biomedical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Psyence Biomedical's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-3.125
	=	0.00

Psyence Biomedical's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-3.125
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Mar. 2023) EBITDA data.

Psyence Biomedical (NAS:PBM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Psyence Biomedical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024